SV LIFE Sciences FUND IV Strategic Partners, L. P. is 10% Owner at KalVista Pharmaceuticals, Inc. (KALV). They have made 7 open-market trades across 4 companies since 2014, most recently 2019-04-02.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $3.0M since 2014, against 6 sales. Too few scored purchases to measure a record yet.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 67% | 67% | 83% |
| Avg Move | -7.3% | +8.2% | -5.6% |
| Scored | 6 | 6 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KALV | SELL | 2019-03-29 | 2019-04-02 | $28.03 | $5.4M | -9.4% | -23.6% | -25.0% |
| KALV | SELL | 2019-03-04 | 2019-03-06 | $22.97 | $3.4M | +22.5% | +41.5% | -9.7% |
| KALV | SELL | 2019-02-19 | 2019-02-21 | $20.55 | $8.8M | +8.5% | +41.0% | +10.7% |
| OCUL | SELL | 2015-06-10 | 2015-06-11 | $22.00 | $16.4M | -35.9% | -1.7% | -1.7% |
| OPHT | SELL | 2014-06-04 | 2014-06-05 | $42.54 | $55.8M | -14.7% | -4.1% | -4.1% |
| TRXC | BUY | 2014-04-21 | 2014-04-23 | $4.00 | $3.0M | -28.3% | -5.7% | -5.7% |
| OPHT | SELL | 2014-02-18 | 2014-02-19 | $29.61 | $41.7M | -14.7% | -4.1% | -4.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.